Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItSelection and expansion of natural killer cells for NK cell-based immunotherapyNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyTumor antigen-specific monoclonal antibodies and induction of T-cell immunityIn vivo monitoring of natural killer cell trafficking during tumor immunotherapyLow Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case reportNK cell-based immunotherapy for malignant diseases.Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses.Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodiesA Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) CellsIdentification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.Present and Future of Allogeneic Natural Killer Cell TherapyImmune microenvironment in tumor progression: characteristics and challenges for therapyImproved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4.A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpGNeuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingNeonatal natural killer cell function: relevance to antiviral immune defenseThe critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.Shaping of NK cell responses by the tumor microenvironmentImmunocytokines: a review of molecules in clinical development for cancer therapy.Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.Neutrophils: important contributors to tumor progression and metastasis."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linkerThe IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function.Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.
P2860
Q21131216-2D565321-B078-4C67-BCFA-94276271B544Q26752780-FB95CDA5-3279-4B3A-A067-85294C939F51Q26774777-A9CE957B-8D20-4E0C-9F9D-C7D717F1A704Q26797345-DC889D80-FD52-4ED1-AD79-01E3370A1A55Q27009908-AD69C1E2-23C4-4B47-9113-ECBB679352FBQ27011245-07533F94-2339-4BA0-92A7-268BAAD8CA65Q30398870-3EE8565A-CD52-49E4-91F4-748D05F6EDE6Q33585293-3600F91A-B16E-40D5-8BD3-081C13A8A8E4Q33748308-8227561A-E346-400A-99CE-F11018EFBB5EQ33827433-D1C15FC7-E13D-40E5-83C3-065B3CEC551FQ34169579-2AD437FB-27C7-4A08-A219-C6FCC3CA6C29Q34275134-3E2CD40B-2BB1-4148-9FE1-5297A5C0794DQ34548847-AB885C46-A5C1-4B7C-9CE3-DE147C075F0AQ34551581-D5E5701B-2011-4A01-ABF0-0DC86774FD71Q35154170-0B99FE5E-FC4C-4863-AE65-75F16BF24EB8Q35542801-F07EDE9E-3CF7-4024-A1EC-838A471ED317Q35588890-3F21114B-90A1-4CBF-9BBA-596210E9845DQ35677351-532FE48B-EB52-4FBD-A2EB-4ED6E8CEF3ABQ36178400-C96E7A7D-FDDF-4F0E-AADB-C48981EF8643Q36247376-C5C38165-2CFD-4C63-8C2F-0BAE7F7CC10CQ36547750-C080C947-4782-4BD1-8DCB-B0DC9CCE1DF6Q36625824-C2A2173D-08C0-4F05-8510-34F5780376AEQ36635664-7DC8F417-3CB3-4E37-8AE2-194F16425E14Q36856792-A5A7B449-D41D-4619-98B2-E4CAE7BB1A28Q37138332-DD7D605E-7148-41D2-9B27-68213882BC31Q37162875-41C80E46-AE9C-4BE0-8178-E31AEFC20E7AQ37413162-78D8F13C-0A35-4306-B815-9F70463797F9Q37434670-E4AF86E8-F17E-4B9B-B833-96A130DEDF19Q38067641-BA9A903B-74E4-4A0D-81BF-C639FFD15577Q38132742-F3998551-59C7-480D-B5FF-5D1ACB575B97Q38233046-E8AE5534-C4A1-4422-8F8F-D9E548535631Q38269777-FEE1A6C6-8DCB-4798-8B9D-12C8DDD43130Q38585102-F28423EF-EFA1-4D80-A8F0-67701D02D2DFQ38723957-223A6D50-1432-4A6B-A267-B91DDE9A3492Q38772382-347D626D-4470-497D-8EFD-F514B53636B6Q38831202-A8DF0D98-6986-4041-B178-8F5A597E6A00Q38912287-5D75669A-6953-4747-AA85-1D228ADF7697Q38915262-BE56ACA8-EB24-4DEA-91E2-57CC3EB910EDQ38920328-9A24FFB1-7214-46CD-B35C-AC94AC007480Q38982777-3A4CE935-E405-44EC-8962-A8106D812B9B
P2860
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
@ast
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
@en
type
label
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
@ast
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
@en
prefLabel
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
@ast
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
@en
P2860
P921
P356
P1476
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
@en
P2093
Kory L Alderson
Paul M Sondel
P2860
P304
P356
10.1155/2011/379123
P577
2011-05-24T00:00:00Z